Autonomous cab company launches Houston pilot program for wheelchair-accessible rides

new to hou

Cruise has partnered with a mobility solutions provider to launch a six-month pilot program offering free wheelchair-accessible transportation in Houston. Photo courtesy of Cruise

A California company with autonomous cabs has announced a new pilot program in partnership with a provider of wheelchairs and mobility solutions.

Cruise has teamed up with Numotion for a six-month wheelchair-accessible vehicle (WAV) pilot program in Houston, offering free transportation for qualifying Numotion customers, according to the companies. The program will operate in over 90 Houston-area ZIP codes.

“Numotion is excited to partner with Cruise to offer a seamless and convenient solution for wheelchair users in the Houston area. By providing transportation to and from repair appointments, we're alleviating a significant stressor and providing a way for our customers to receive their service and repair faster,” says Mike Swinford, CEO of Numotion, in a news release. “We're constantly striving to innovate and improve the lives of our customers, and this collaboration demonstrates our ongoing commitment to providing beneficial customer experiences."

Cruise entered the Texas market last year, with Houston services launching in October 2023 before the company put all operations on pause following a California crash. This is the first Texas announcement for Cruise since the pause.

"Accessibility is core to our mission at Cruise. This pilot program with Numotion is doing more than providing accessible rides – it’s about empowering people in the community with greater mobility and independence, while also building learnings to better our service in the future," says Craig Glidden, president and chief administrative officer at Cruise about the new pilot.

From Your Site Articles
PUSH Birth Partners will also soon host several support groups for pregnant people focused on improving mental health. Photo courtesy of Jacqueline McLeeland

Innovative Houston nonprofit partners with county organization to provide maternal health services

TEAM WORK

PUSH Birth Partners, a Houston-based maternal health nonprofit, is teaming up with the Harris County Public Health Department to provide doula services for over 200 pregnant people free of cost.

Jacqueline McLeeland, CEO and founder of PUSH, says the program will begin in August and aims to improve maternal health and birth outcomes for vulnerable populations. McLeeland says the organization has built up a strong doula training program through their collective in partnership with March of Dimes and several local doula organizations.

McLeeland says PUSH aims to address poor maternal health outcomes for women of color in part by training more doulas of color who can help reduce racial disparities in care. A 2021 study by Harris County Public Health found Precinct 1, which is predominantly composed of people of color, had the highest maternal mortality rate of the county.

Through their collective, PUSH has trained two cohorts of doulas through an integrated care model, focused on providing collaborative care with medical providers in the healthcare system.

“Our programs are designed to advance health equity, we see the numbers, we see that women of color, specifically Black women in that group are disproportionately impacted,” McLeeland tells InnovationMap.

After receiving a $100,000 grant from the Episcopal Health Foundation in 2023, PUSH began their doula expansion program in Houston and they have since received an additional grant from EHF for the next fiscal year. McLeeland shares PUSH has also launched a pilot program called Blossoming Beyond Birth, sponsored by the Rockwell Fund, targeted towards improving maternal mental health through weekly support groups in Houston.

“It’s very exciting to know that we have come this far from where we started and to see how everything is coming together,” McLeeland shares.

Jacqueline McLeeland serves as chief executive and founder of non-profit PUSH Birth Partners who has trained and collaborated with a network of doulas for the partnership. Photo courtesy of Jacqueline McLeeland

For McLeeland, improving maternal health outcomes and providing support to people experiencing high-risk pregnancies are deeply personal goals. McLeeland has sickle cell anemia, a condition that can cause serious complications during pregnancy. During her first pregnancy in 2015, McLeeland was placed on bed rest two months before her due date at which point she had been working in clinical research within the pharmaceutical industry for over 12 years.

“People don’t realize the magnitude of what women go through, during pregnancy and after,” McLeeland says. “There’s a lot of emotional, psychological, and physical tolls depending on how the pregnancy and delivery went.”

After giving birth to her first child, McLeeland took maternity leave, during which she began to research maternal morbidity and mortality trends, information which she says was not widely discussed at the time.

McLeeland says entering the maternal healthcare field felt like a necessity following her second pregnancy. Several months after giving birth to her second child, McLeeland says she received a bill for a surgical procedure that was performed during her cesarean section without her or her husband’s consent. McLeeland says that was the first time she was made aware of the surgery.

“The procedure that was claimed to have been performed could have put my life in jeopardy by hemorrhaging based off of additional research I did once, I came across that information,” McLeeland explains. “These are some of the things that happen in the healthcare system that make people skeptical of trusting in the healthcare system, trusting in doctors.”

McLeeland says the key to improving maternal and birth outcomes for vulnerable populations is to encourage the partnership between doulas, community healthcare workers, and physicians and hopes to further this collaboration through future programming.

The funding will go toward created a summer program called the University of Houston Cardiovascular Undergraduate Research Experience, or UH-CURE. Photo via UH.edu

University of Houston receives funding to support diverse cardiovascular researchers

pumping up innovation

University of Houston professors have received a nearly $800,000 grant to create a new summer program that will support diverse future researchers.

The National Heart, Lung, and Blood Institute provided $792,900 in grant funding to Bradley McConnell, professor of pharmacology at the UH College of Pharmacy, and Tho Tran, research assistant professor of chemistry at the UH College of Natural Sciences and Mathematics.

The funding will go toward created a summer program called the University of Houston Cardiovascular Undergraduate Research Experience, or UH-CURE. Ten undergraduate students per year will be selected for five years in cardiovascular research across disciplinary lines.

"We are so grateful to be able to provide talented students across the U.S. an opportunity to experience our excellent cardiovascular research environment,” Tran says in a news release. “We want UH-CURE participants to gain confidence in their research abilities through our hands-on approach and the skillset to navigate future challenges through our professional training.”

The goal is to increase students’ interest in cardiovascular research, and students have the opportunity to receive a $6,000 stipend, travel to a globally recognized cardiovascular research conference, and take part in on-campus housing and a food allowance. The summer program will also try to develop research skills, increase awareness of transdisciplinary research, promote diversity and collaborations, cultivate transferable skills necessary for succeeding in graduate school and help facilitate undergraduate students to pursue further training in cardiovascular research.

The program will integrate students into a research lab where they will learn research skills, data analysis, and research integrity. The program will be under the mentorship of a faculty member from across UH’s colleges, and include workshop and enrichment activities.

McConnell and Tran previously formed the American Heart Association-funded UH-HEART pilot program, which focused on cardiovascular research. They expanded on that initiative with UH-CURE, which includes cardiovascular research across disciplinary lines from community engagement and population-based research to basic, translational, and applied research. UH-CURE also helps prepare for careers in cardiovascular research.

“We all know that a diverse environment leads to a much better generation of ideas and solutions,” Tran adds. “We hope to bring that strength to the future of cardiovascular research through our students.”

Tho Tran (left) and Bradley McConnell are professors at UH. Photo via UH.edu

Redemption Square in Generation Park will feature high-tech parking solution pilot program. Photo via generationpark.com

Houston developer to roll out innovative pilot to improve parking at major development

testing tech

Houston real estate company McCord Development will roll out an innovative 12-week pilot to learn how to make parking smarter at its master planned development Generation Park in Northeast Houston.

In partnership with Milwaukee-based CivicSmart Inc., a leader in Smart City parking, the company will test a new Internet-of-Things-based parking solution at Generation Park's mixed-use lifestyle center, Redemption Square. The program is only the second of its kind in the U.S., according to McCord.

McCord will install 30 of CivicSmart's solar powered bollards at Redemption Square that track real-time parking occupancy data through LTE license-plate-reading cameras. The data will be analyzed to help McCord optimize traffic and develop better strategies and parking rates.

"We are thrilled to introduce one of the first parking pilot programs in the country,” Ashwin Chandran, Director of Technology Innovation at McCord, said in a statement. “At McCord, we strive to measure and understand behavior in order to enhance the human experience and make efficient business decisions. We hope to use this data to improve the overall performance of our operations across all our assets.”

According to the statement, the intention of the program is to help keep curbside spots available for short-term guests.

From the customer perspective, parkers will pay via text or QR code, where they will enter their license plate number and payment information, which will be stored for subsequent visits.

The bollards can also dispatch up-to-the-minute pricing details to parkers, and can be controlled remotely by the developer to close certain parking spots for special events.

In addition to the 30 bollards, Redemption Square will still also offer free parking in its nearby garage, and other parking options on Redemption Square Road and metered spaces on Assay Street, according to the statement.

Last week, McCord also announced plans to create a 45-acre biomanufacturing campus within the 4,300-acre Generation Park development. Known as BioHub Two, the center will include 500,000 square feet for manufacturing, lab, and office space. It's slated to join San Jacinto College’s Biotech Training Center in the development, which was announced last December.

Other plans for Generation Park include two multifamily complexes, a mixed-use development called The Commons, and retail and green spaces.

McCord will install 30 of CivicSmart's solar powered bollards at Redemption Square that track real-time parking occupancy data through LTE license-plate-reading cameras. Photo courtesy of Generation Park

A Houston pilot program created a way to design stylish homes at a fraction of the cost — and in less than half the time. Photo courtesy of BoxPrefab

Houston-grown partnership completes innovative pilot program promoting affordable housing

innovating an impact

For families who want to live near downtown, Houston's affordable housing deficit in and around the Inner Loop is no secret.

For thirty years and counting, Houston-based nonprofit Avenue has confronted this reality by creating affordable housing opportunities and comprehensive community development programs for families in Houston neighborhoods.

"One of our chief objectives is to help stabilize neighborhoods and give opportunities for people to stay in the neighborhoods by providing moderately-priced homes," says Robert Fiederlein, Avenue's senior director of real estate development.

After an audit of Houston's Northline neighborhood revealed the community's affordable housing shortage, the Avenue team began to explore various methods to deliver new construction to the community, through sustainable housing at affordable prices. Research of diverse construction methods led Avenue to the innovative solution of prefabricated family dwellings.

In their effort to find a smart, sustainable alternative to traditional construction, Avenue came across BoxPrefab, an innovative off-site construction company that produces precision-built prefabricated homes from design to completion.

BoxPrefab's sustainable-oriented attributes and efficient processes checked all of Avenue's 'must-have' boxes and the two entities kicked off their partnership with their premier pilot program for modular home development.

"We care a lot about bringing affordability to housing and bringing good designs to affordable housing. We were really excited to work with Avenue because we are really in tune with their mission," says Rame Hruska, BoxPrefab's co-founder. "This is a great solution for homeowners."

This housing solution is not your run-of-the-mill "affordable housing." Besides its sleek finishes and modern look, BoxPrefab's modular home design and construction process is practical and ultra-simplified. Using prefabricated components, the company specializes in building homes in a factory, a controlled environment, instead of building on-site, where the construction process is subject to external variables, like rain, inclement weather, or any labor diversions.

The BoxPrefab houses are created offsite and then set up on the property. Photo courtesy of BoxPrefab

"Reliability is a big factor for our clients. There's so many unknowns and variables, from weather to other various delays, so we can really give people a much more definitive price, time and set quality," says Hruska.

After producing the factory-built components, BoxPrefab then assembles the prefabricated modules on the home's lot. With this streamlined process, BoxPrefab is able to build homes faster and in a more systematic manner, all while reducing waste output and overall cost.

"We have confidence that if we placed higher orders, costs would go down," Fiederlein says. "This could be a way to build less costly affordable housing. Construction costs came out $130 per square foot, which is comparable to the other site-built homes that we're working on right now.

"Another thing we've learned was that we can do it in half the time as a site build," Fiederlein continues. "It takes six to seven months to build a site-built home and we completed this home in just over three months. Russell, with tighter scheduling, said he could've built quicker. We can half the time it would normally take. As you know, time is money."

BoxPrefab's construction process, fiscal efficiency and waste output reduction is exactly what Avenue was looking for in a partner. Together, the two entities successfully completed their pilot program by placing a three-bedroom-two-bathroom prefabricated home on the market in Houston's Northline neighborhood.

"We're really excited about this potential and see it as becoming a much more standard way to build," Hruska says.

Prefabricated building options are considered the future of construction, due to its increased reliability and quality in the construction process, Hruska says. Based on the success of their pilot program, Avenue anticipates investing in more modular housing in the future. BoxPrefab, while Houston-based and focused, has their sights set on expanding regionally, to service more clients with prefabricated solutions, says Russell Hruska, BoxPrefab co-founder.

"Modular is a viable path going forward," Fiederlein says. "It's going to take additional work to get there, but the pilot shows that it's certainly a method that helps to reduce costs…We're confident that it can be the way of delivering affordable housing at lower prices."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings